AbCellera Biologics Inc (ABCL)

[LQMT_Monster]

Any sign of life in here?

[Monksdream]

ABCL new 52 week low

[Monksdream]

Using AI to find the next blockbuster drug
This week, AI chipmaker Nvidia placed their bet — investing $50M into AI drug discovery platform Recursion Pharmaceuticals (NASDAQ:RXRX) — sending its stock up 78%.
Drugmakers are already benefiting from using AI to discover new drugs. And in the process, AI is speeding up and reducing the cost of the long and expensive drug development process.
Between 2015 and 2022, the cumulative investment in AI drug development has risen from under $1B to $24.6B.
In the next decade, Morgan Stanley expects AI will help develop an additional 50 drugs with an extra $50B in sales.
Following Nvidia’s investment, other AI drug discovery platforms rose on the news, including Exscientia (NASDAQ:EXAI), AbCellera Biologics (NASDAQ:ABCL) and Relay Therapeutics (NASDAQ:RLAY).
Recursion has five drugs, and Exscientia has three drugs discovered with AI, which are already in human trials. And within the startup sector, AI drug discovery has quickly become one of the hottest markets for investment.

[Jayzp]

THER MEME STOCK TO BUY NOW
GOOD NEEDS

THER CAN GO BACK TO 1$

https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html

[Bill Harford]

I read this company is using AI for biotech. Anyone have more info on that?

[the_stockoracle]

Wouldn’t buy this until I see a real uptrend it’s constantly making lower lows

[mrPiNK]

Gamma short squeeze coming. Enjoy

[Nebuchadnezzar]

ya right. good luck with that

[Marvy]

79% of float held by insiders and institutions

[crudeoil24]

Quiet evening, most investors, tutes & traders are at the beach...lol.

ABCL

[dinogreeves]

I agree totally, was on the phone with a friend, told him about it and I said to him, this should open at 30 plus tomorrow.

[crudeoil24]

May see opening bell gap @ 35.00+ FRIDAY.

[crudeoil24]

Young teenagers will be prime beneficiaries.

[beginneer]

Loving it. Glad i bought it yesterday. No vaccine? No problem!!! Hehehe

[crudeoil24]

Tomorrow will see massive accumulation >

ABCL

[crudeoil24]

163M trading float >

[dinogreeves]

Monday-Wedsday that is where we will sitting at.

[crudeoil24]

$71.00 > 52 week high >

ABCL

[crudeoil24]

AbCellera (NASDAQ:ABCL) today announced the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg administered with etesevimab (LY-CoV016) 1400 mg to include post-exposure prophylaxis (PEP) to prevent SARS-CoV-2 infection or symptomatic COVID-19. The neutralizing antibodies, which were authorized together by the FDA in February 2021 to treat early COVID-19 infection, can now also be used together to treat high-risk individuals 12 years of age and older who have not been fully vaccinated against COVID-19 or are not expected to mount an adequate immune response to complete vaccination, and have been exposed to someone infected with SARS-CoV-2 or who are at high risk of exposure in an institutional setting, including a nursing home or prison.

"The expanded use authorization for bamlanivimab together with etesevimab provides a way to protect the significant number of people who, because of their situational exposure risk or medical condition, remain vulnerable to COVID-19," said Carl Hansen, Ph.D., CEO and President of AbCellera. "More than 535,000 patients have been treated with bamlanivimab alone or together with etesevimab, potentially keeping more than 25,000 patients out of the hospital and saving more than 10,000 lives. With this expanded authorization, these antibodies, which have been shown to be effective against the highly contagious Delta variant, can now be used to protect some of the most at-risk people exposed to the virus."

The expanded EUA is based on data from the Phase 3 BLAZE-2 trial that showed bamlanivimab prevented COVID-19 in nursing homes, reducing the risk of contracting the disease by up to 80 percent in nursing home residents and up to 57 percent among residents and staff of long-term care facilities. Eli Lilly and Company's (Lilly) study was conducted in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the COVID-19 Prevention Network (CoVPN).

Pseudovirus and authentic virus studies demonstrate that bamlanivimab and etesevimab together retain neutralization activity against the Alpha and Delta variants. On September 2nd, the Office of the Assistant Secretary for Preparedness and Response (ASPR), alongside the FDA, resumed the shipment and distribution of bamlanivimab and etesevimab administered together.

For information about the use of bamlanivimab and etesevimab together for the treatment and prevention of mild to moderate COVID-19 in high-risk patients under the FDA's emergency use authorization, please click here or contact Lilly's 24-hour support line at 1-855-LillyC19 (1-855-545-5921).

About AbCellera's Response to COVID-19

AbCellera initially mobilized its pandemic response platform against COVID-19 in March of 2020, resulting in the discovery of bamlanivimab, the first monoclonal antibody therapy for COVID-19 to reach human testing and to be authorized for emergency use by the FDA. Bamlanivimab alone and together with other antibodies has treated hundreds of thousands of patients, preventing COVID-19-related hospitalizations and death.

AbCellera's ongoing efforts to respond to the COVID-19 pandemic have identified thousands of unique anti-SARS-CoV-2 human antibodies. These include bamlanivimab, bebtelovimab, and other antibodies that are in various stages of testing by AbCellera and its partners.

AbCellera's pandemic response capabilities were developed over the past three years as part of the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program. The goal of the P3 program is to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen.

[dinogreeves]

ABCL is the next Moderna

[Methinks]

This stock was mentioned

on a youtube video about a different stock from, I believe, Bestofusinvestors.com and it was highly recommended.

[AliasUser1]

Big volume today. Pretty solid rebound so far. Could become something.

[kzivann]

Was short term for me..gl


ABCL

[AliasUser1]

Brutal here. RSI below 30 on daily and weekly charts, wonder when a bottom occurs. Feels like we could get a big dip and rip bottom here. Maybe a -10% or -15% day then rips to the upside.

[AliasUser1]

Wonder when this bottoms. $ABCL

[kzivann]

Thanks. Always nice when you buy at a bottom.

ABCL

[AliasUser1]

Great timing on that!

[kzivann]

Been going down and down. Bottom perhaps. In for a small bit.


ABCL

[AliasUser1]

Ready to buy more if we get a good pullback. $ABCL

[AliasUser1]

Room to run up ahead of 5/13 earnings. $ABCL

[AliasUser1]

Thinking the chart is turning around. Long term $ABCL will be big imo, A new drug discovery platform.

[AliasUser1]

$ABCL could be big. Backed-by Thiel Gates DARPA. Good business plan on not having to run clinical trials, and instead collect upfront payments and then royalies.

Full-stack, AI-powered therapeutic antibody drug discovery platform.

[StockRoomBully]

P3 program finally Abcellera in the public eye

[New$tockguy]

Thoughts...

[JJ34]

First.